PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines

168

 (Pan American Heath Organisation Press Release) – The Pan American Health Organization (PAHO) has announced the selection of two centers in Argentina and Brazil as regional hubs for the development and production of mRNA-based vaccines in Latin America in a bid to tackle COVID-19 and future infectious-disease challenges.

The Bio-Manguinhos Institute of Technology on Immunobiologicals at the Oswaldo Cruz Foundation (FIOCRUZ) was selected as the center in Brazil. The institute has a long tradition in vaccine manufacturing and has made promising advances in the development of an innovative mRNA vaccine against COVID-19.

“Delays in production have meant that many countries [in the region] are still awaiting the doses they purchased months ago. Limited vaccine supplies continue to set us back. This limited production and unequal distribution of vaccines in the face of staggering demand hinder our COVID response in the Americas. Mass vaccination is critical.” – PAHO Director Dr. Carissa F. Etienne

Sinergium Biotech, a private sector biopharmaceutical company, was selected as the center in Argentina. Sinergium will partner with pharmaceutical mAbxience, which belongs to the same group, to develop and manufacture active vaccine ingredients. The two companies have extensive experience in the production and development of vaccines and biotechnological medicines.

The announcement was made by Dr. Soumya Swaminathan, World Health Organization (WHO) Chief Scientist, and PAHO Assistant Director Dr Jarbas Barbosa during a side event on the margins of PAHO’s 59th Directing Council. The “Technology Transfer for the Production of mRNA Vaccines in the Americas” event brought together health ministers and authorities from countries in the region to discuss vaccine production.

Read more at: Pan American Health Organisation

Comments are closed.

%d bloggers like this: